Roche reports new 6-year OCREVUS (ocrelizumab) data from MS study
Roche announced longer-term data from the Phase III open-label extension studies of OPERA I, OPERA II and ORATORIO showed patients who were treated with OCREVUS® (ocrelizumab) continuously for six years or more had reduced risk of disability progression in RMS and primary PPMS. September 13, 2019